PF-Atlas › Treatments › Rentosertib / ISM001-055

Rentosertib / ISM001-055

First-in-class TNIK kinase inhibitor — blocks TRAF2/NCK-interacting kinase driving fibrosis and inflammation

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.

Development stage

Phase IIa (Nature Medicine 2025)

Evidence level

Level 2 (Phase IIa)

Mechanism class

First-in-class TNIK kinase inhibitor — blocks TRAF2/NCK-interacting kinase driving fibrosis and inflammation

Timeline

2-3 years

Risk profile

Low-Medium

Developer

Insilico Medicine

Key researchers

A. Zhavoronkov

Overview

FIRST AI-DISCOVERED DRUG validated in clinical trial. Published Nature Medicine June 2025. 60mg QD: mean FVC change +98.4 mL vs -20.3 mL placebo. Novel target TNIK discovered entirely by generative AI (Pharma.AI). Historic milestone for AI drug discovery.

How Rentosertib / ISM001-055 fits into IPF treatment

Rentosertib / ISM001-055 is classified as Level 2 (Phase IIa) at the Phase IIa (Nature Medicine 2025) stage. Explore how it compares to other options and where it sits in the development pipeline:

Rentosertib drug profile First-in-class TNIK kinase inhibitor — blocks TRAF2/NCK-interacting kinase driving fibrosis and inflammation Clinical trials Drug pipeline Research

Other IPF treatments

Nerandomilast / Jascayd Inhaled Treprostinil / Tyvaso Admilparant / BMS-986278 AI Knowledge Graph uPAR-CAR-T Senolytic Immunotherapy Senolytics + WNT Agonist Combination

Medical disclaimer. This page summarizes published research and PF-Atlas model output about Rentosertib / ISM001-055 for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.